Download PDF
Zentralbl Chir 2020; 145(02): 160-167
DOI: 10.1055/a-1117-4143
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Systemische Therapieoptionen bei lokal fortgeschrittenen und metastasierten myxoiden, dedifferenzierten und pleomorphen Liposarkomen

Systemic Therapy Options for Locally Advanced and Metastatic Myxoid, Dedifferentiated and Pleomorphic Liposarcoma
Daniel Pink
1   Klinik für Hämatologie, Onkologie und Palliativmedizin – Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, Deutschland
2   Klinik und Poliklinik für Innere Medizin C – Hämatologie und Onkologie und Transplantationszentrum, Universitätsmedizin Greifswald, Deutschland
,
Antje West
1   Klinik für Hämatologie, Onkologie und Palliativmedizin – Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, Deutschland
,
Dimosthenis Andreou
3   Abteilung für Tumororthopädie und Sarkomchirurgie, Klinik für Traumatologie und Orthopädie – Sarkomzentrum Berlin-Brandenburg, HELIOS Klinikum Bad Saarow, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2020 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Noch vor wenigen Jahren haben alle Patienten mit metastasierten Weichteilsarkomen die gleiche Chemotherapie erhalten. Infolge der Erkenntnis, dass es sich bei den verschiedenen Sarkomsubtypen um unterschiedliche Erkrankungen mit unterschiedlichen genetischen Veränderungen und einem unterschiedlichen biologischen Verhalten handelt, wurden allerdings in letzter Zeit zunehmend subtypspezifische medikamentöse Therapieprotokolle eingesetzt. Selbiges gilt auch für die verschiedenen Subtypen von Liposarkomen – das myxoide/rundzellige Liposarkom, das dedifferenzierte Liposarkom und das pleomorphe Liposarkom. In diesem Beitrag werden publizierte Daten und Erfahrungen mit unterschiedlichen systemischen Therapieoptionen in den verschiedenen Therapielinien sowie ein Überblick über experimentelle Therapieansätze präsentiert.

Abstract

Just a few years ago, all patients with metastatic soft tissue sarcoma received the same chemotherapy drugs. However, it is now recognised that the various sarcoma subtypes are different tumours with distinct genetic alterations and different biological behaviour, so that histology-specific treatment protocols have been increasingly implemented in recent years. This is also the case for the different subtypes of liposarcoma – the myxoid/round cell variant, as well as dedifferentiated and pleomorphic liposarcoma. This article will present published data and the authorsʼ experience with the various systemic treatment options. both in first line and in subsequent lines of treatment, as well as a brief overview of experimental treatment approaches.

Schlüsselwörter

Liposarkom - Chemotherapie - Sarkom - myxoid - dedifferenziert - pleomorph

Key words

liposarcoma - chemotherapy - sarcoma - myxoid - dedifferentiated - pleomorphic
 

  • Literatur

  • 1 Van Glabbeke M, van Oosterom AT, Oosterhuis JW. et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens–a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 1999; 17: 150-157
    CrossrefPubMedGoogle Scholar
  • 2 Judson I, Verweij J, Gelderblom H. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15: 415-423
    CrossrefPubMedGoogle Scholar
  • 3 Tap WD, Papai Z, Van Tine BA. Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2017; 18: 1089-1103
    CrossrefPubMedGoogle Scholar
  • 4 Tap WD, Wagner AJ, Papai Z. et al. ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). J Clin Oncol 2019; 37 (18 Suppl.): Abstract. LBA3
    PubMedGoogle Scholar
  • 5 Grilley-Olson JE, Webber NP, Demos DS. et al. Multidisciplinary management of oligometastatic soft tissue sarcoma. Am Soc Clin Oncol Educ Book 2018; 38: 939-948
    PubMedGoogle Scholar
  • 6 Harris SJ, Maruzzo M, Thway K. et al. Metastatic soft tissue sarcoma, an analysis of systemic therapy and impact on survival. J Clin Oncol 2015; 33 (15 Suppl.): 10545-10545
    CrossrefPubMedGoogle Scholar
  • 7 Minchom A, Jones RL, Fisher C. et al. Clinical benefit of second-line palliative chemotherapy in advanced soft-tissue sarcoma. Sarcoma 2010; 2010: 264360
    PubMedGoogle Scholar
  • 8 Martín Broto J, Le Cesne A, Reichardt P. The importance of treating by histological subtype in advanced soft tissue sarcoma. Future Oncol 2017; 13: 23-31
    PubMedGoogle Scholar
  • 9 Jones RL, Fisher C, Al-Muderis O. et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41: 2853-2860
    CrossrefPubMedGoogle Scholar
  • 10 Lee ATJ, Thway K, Huang PH. et al. Clinical and molecular spectrum of liposarcoma. J Clin Oncol 2018; 36: 151-159
    PubMedGoogle Scholar
  • 11 Grethlein SJ. Histology driven systemic therapy of liposarcoma-ready for prime time?. Transl Gastroenterol Hepatol 2018; 3: 96
    CrossrefPubMedGoogle Scholar
  • 12 Patel S, von Mehren M, Reed DR. et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer 2019; 125: 2610-2620
    CrossrefPubMedGoogle Scholar
  • 13 Italiano A, Garbay D, Cioffi A. et al. Advanced pleomorphic liposarcomas: clinical outcome and impact of chemotherapy. Ann Oncol 2012; 23: 2205-2206
    CrossrefPubMedGoogle Scholar
  • 14 McGovern Y, Zhou CD, Jones RL. Systemic therapy in metastatic or unresectable well-differentiated/dedifferentiated liposarcoma. Front Oncol 2017; 7: 292
    CrossrefPubMedGoogle Scholar
  • 15 Gebhard S, Coindre JM, Michels JJ. et al. Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol 2002; 26: 601-616
    CrossrefPubMedGoogle Scholar
  • 16 Seddon B, Strauss SJ, Whelan J. et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. Lancet Oncol 2017; 18: 1397-1410
    CrossrefPubMedGoogle Scholar
  • 17 Tap WD, Jones RL, Van Tine BA. et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 2016; 388: 488-497
    CrossrefPubMedGoogle Scholar
  • 18 Italiano A, Toulmonde M, Cioffi A. et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol 2012; 23: 1601-1607
    CrossrefPubMedGoogle Scholar
  • 19 Katz D, Boonsirikamchai P, Choi H. et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma. Clin Sarcoma Res 2012; 2: 2
    CrossrefPubMedGoogle Scholar
  • 20 Bitz U, Pink D, Busemann C. et al. Doxorubicin (Doxo) and dacarbacin (DTIC) as first-line therapy for patients (pts) with locally advanced or metastatic leiomyosarcoma (LMS) and liposarcoma (LPS). J Clin Oncol 2011; 29 (15 Suppl.): 10094
    CrossrefPubMedGoogle Scholar
  • 21 Patel SR, Burgess MA, Plager C. et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer 1994; 74: 1265-1269
    CrossrefPubMedGoogle Scholar
  • 22 Colia V, Fumagalli E, Provenzano S. et al. High-dose ifosfamide chemotherapy in a series of patients affected by myxoid liposarcoma. Sarcoma 2017; 2017: 3739159
    PubMedGoogle Scholar
  • 23 Sanfilippo R, Bertulli R, Marrari A. et al. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. Clin Sarcoma Res 2014; 4: 16
    CrossrefPubMedGoogle Scholar
  • 24 Demetri GD, Chawla SP, von Mehren M. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4189
    CrossrefPubMedGoogle Scholar
  • 25 Demetri GD, von Mehren M, Jones RL. et al. Efficacy and safety of trabectedin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicenter clinical trial. J Clin Oncol 2016; 34: 786-793
    CrossrefPubMedGoogle Scholar
  • 26 Patel S, von Mehren M, Reed DR. et al. Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma. Cancer 2019; 125: 2610-2620
    CrossrefPubMedGoogle Scholar
  • 27 Grosso F, Jones RL, Demetri GD. et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595-602
    CrossrefPubMedGoogle Scholar
  • 28 Schöffski P, Chawla S, Maki RG. et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016; 387: 1629-1637
    CrossrefPubMedGoogle Scholar
  • 29 Demetri GD, Schöffski P, Grignani G. et al. Activity of eribulin in patients with advanced liposarcoma demonstrated in a subgroup analysis from a randomized phase III study of eribulin versus dacarbazine. J Clin Oncol 2017; 35: 3433-3439
    CrossrefPubMedGoogle Scholar
  • 30 Maki RG, Wathen JK, Patel SR. et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25: 2755-2763
    CrossrefPubMedGoogle Scholar
  • 31 Miyake K, Higuchi T, Oshiro H. et al. The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model. Biomed Pharmacother 2019; 117: 109093
    CrossrefPubMedGoogle Scholar
  • 32 van der Graaf WT, Blay JY, Chawla SP. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379: 1879-1886
    CrossrefPubMedGoogle Scholar
  • 33 Sleijfer S, Ray-Coquard I, Papai Z. et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27: 3126-3132
    CrossrefPubMedGoogle Scholar
  • 34 Samuels BL, Chawla SP, Somaiah N. et al. Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Cancer 2017; 123: 4640-4647
    CrossrefPubMedGoogle Scholar
  • 35 Seto T, Song MN, Trieu M. et al. Real-world experiences with pazopanib in patients with advanced soft tissue and bone sarcoma in northern California. Med Sci (Basel) 2019; 7 pii: E48
    PubMedGoogle Scholar
  • 36 Mahmood ST, Agresta S, Vigil CE. et al. Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma. Int J Cancer 2011; 129: 1963-1969
    CrossrefPubMedGoogle Scholar
  • 37 Mir O, Brodowicz T, Italiano A. et al. Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2016; 17: 1732-1742
    CrossrefPubMedGoogle Scholar
  • 38 von Mehren M, Rankin C, Goldblum JR. et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer 2012; 118: 770-776
    CrossrefPubMedGoogle Scholar
  • 39 Paoluzzi L, Cacavio A, Ghesani M. et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res 2016; 6: 24
    CrossrefPubMedGoogle Scholar
  • 40 DʼAngelo SP, Mahoney MR, Van Tine BA. et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 2018; 19: 416-426
    CrossrefPubMedGoogle Scholar
  • 41 Tawbi HA, Burgess M, Bolejack V. et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol 2017; 18: 1493-1501
    CrossrefPubMedGoogle Scholar
  • 42 Wilky BA, Trucco MM, Subhawong TK. et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol 2019; 20: 837-848
    CrossrefPubMedGoogle Scholar
  • 43 Chawla SP, Sankhala KK, Ravicz J. et al. Clinical experience with combination chemo-/immunotherapy using trabectedin and nivolumab for advanced soft tissue sarcoma. J Sarcoma Res 2018; 2: 1009
    PubMedGoogle Scholar
  • 44 Florou V, Rosenberg AE, Wieder E. et al. Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution. J Immunother Cancer 2019; 7: 213
    CrossrefPubMedGoogle Scholar
  • 45 Dufresne A, Meurgey A, Brahmi M. Immunotherapy of heterogenous sarcomas: questions and strategies. Curr Opin Oncol 2019; 31: 304-309
    CrossrefPubMedGoogle Scholar
  • 46 Dickson MA, Tap WD, Keohan ML. et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31: 2024-2028
    CrossrefPubMedGoogle Scholar
  • 47 Demetri GD, Fletcher CD, Mueller E. et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A 1999; 96: 3951-3956
    CrossrefPubMedGoogle Scholar
  • 48 Debrock G, Vanhentenrijk V, Sciot R. et al. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-1412
    CrossrefPubMedGoogle Scholar
  • 49 Pishvaian MJ, Marshall JL, Wagner AJ. et al. A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies. Cancer 2012; 118: 5403-5413
    CrossrefPubMedGoogle Scholar
  • 50 Robbins PF, Morgan RA, Feldman SA. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011; 29: 917-924
    CrossrefPubMedGoogle Scholar
  • 51 Somaiah N, Block MS, Kim JW. et al. First-in-class, first-in-human study evaluating LV305, a dendritic-cell tropic lentiviral vector, in sarcoma and other solid tumors expressing NY-ESO-1. Clin Cancer Res 2019; 25: 5808-5817
    CrossrefPubMedGoogle Scholar
  • 52 Gronchi A, Ferrari S, Quagliuolo V. et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol 2017; 18: 812-822
    CrossrefPubMedGoogle Scholar
  • 53 Schuler MK, Gerdes S, West A. et al. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy – a retrospective study including 32 patients. BMC Cancer 2016; 16: 619
    CrossrefPubMedGoogle Scholar
  • 54 Issels RD, Lindner LH, Verweij J. et al. Effect of neoadjuvant chemotherapy plus regional hyperthermia on long-term outcomes among patients with localized high-risk soft tissue sarcoma: The EORTC 62961-ESHO 95 randomized clinical trial. JAMA Oncol 2018; 4: 483-492
    CrossrefPubMedGoogle Scholar